Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2025)
Historic Gross Margin for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to 95.26%.
- Zevra Therapeutics' Gross Margin rose 575000.0% to 95.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.66%, marking a year-over-year increase of 103700.0%. This contributed to the annual value of 68.59% for FY2024, which is 235000.0% down from last year.
- Latest data reveals that Zevra Therapeutics reported Gross Margin of 95.26% as of Q3 2025, which was up 575000.0% from 52.2% recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Gross Margin ranged from a high of 100.0% in Q3 2021 and a low of 19.69% during Q2 2024
- Moreover, its 5-year median value for Gross Margin was 94.96% (2024), whereas its average is 85.26%.
- Per our database at Business Quant, Zevra Therapeutics' Gross Margin plummeted by -723200bps in 2024 and then surged by 575000bps in 2025.
- Quarter analysis of 5 years shows Zevra Therapeutics' Gross Margin stood at 97.71% in 2021, then rose by 1bps to 98.91% in 2022, then decreased by -9bps to 90.5% in 2023, then dropped by -2bps to 88.63% in 2024, then increased by 7bps to 95.26% in 2025.
- Its Gross Margin was 95.26% in Q3 2025, compared to 52.2% in Q2 2025 and 93.41% in Q1 2025.